EMA signs off on Sanofi and GSK's BARDA-funded Covid booster shot
The European Medicines Agency on Thursday offered a positive recommendation for the first protein-based adjuvanted Covid-19 booster in Europe, developed by Sanofi and GSK.
The BARDA-funded vaccine, known as VidPrevtyn Beta, contains a version of the spike protein found on the surface of the Beta variant of the coronavirus, and an adjuvant to strengthen the immune response.
The EMA’s human medicines committee said Thursday that there are sufficiently robust data on the quality, safety and immunogenicity of the vaccine to recommend its marketing authorization.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 154,000+ biopharma pros reading Endpoints daily — and it's free.